DE69911241D1 - 1,4-diazabicyclo(3.2.2)nonanderivate, deren herstellung und deren verwendung in heilkunde - Google Patents

1,4-diazabicyclo(3.2.2)nonanderivate, deren herstellung und deren verwendung in heilkunde

Info

Publication number
DE69911241D1
DE69911241D1 DE69911241T DE69911241T DE69911241D1 DE 69911241 D1 DE69911241 D1 DE 69911241D1 DE 69911241 T DE69911241 T DE 69911241T DE 69911241 T DE69911241 T DE 69911241T DE 69911241 D1 DE69911241 D1 DE 69911241D1
Authority
DE
Germany
Prior art keywords
nonanderives
diazabicyclo
healthcare
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69911241T
Other languages
English (en)
Other versions
DE69911241T2 (de
Inventor
Alistair Lochead
Samir Jegham
Alain Nedelec
Frederic Galli
Jean Jeunesse
Luc Even
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Application granted granted Critical
Publication of DE69911241D1 publication Critical patent/DE69911241D1/de
Publication of DE69911241T2 publication Critical patent/DE69911241T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69911241T 1998-12-04 1999-12-01 1,4-diazabicyclo(3.2.2)nonanderivate, deren herstellung und deren verwendung in heilkunde Expired - Lifetime DE69911241T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9815326A FR2786770B1 (fr) 1998-12-04 1998-12-04 Derives de 1,4-diazabicyclo[3.2.2.]nonane, leur preparation et leur application en therapeutique
FR9815326 1998-12-04
PCT/FR1999/002975 WO2000034279A1 (fr) 1998-12-04 1999-12-01 Derives de 1,4-diazabicyclo[3.2.2]nonane, leur preparation et leur application en therapeutique

Publications (2)

Publication Number Publication Date
DE69911241D1 true DE69911241D1 (de) 2003-10-16
DE69911241T2 DE69911241T2 (de) 2004-07-01

Family

ID=9533582

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69911241T Expired - Lifetime DE69911241T2 (de) 1998-12-04 1999-12-01 1,4-diazabicyclo(3.2.2)nonanderivate, deren herstellung und deren verwendung in heilkunde

Country Status (9)

Country Link
US (1) US6407095B1 (de)
EP (1) EP1135389B1 (de)
JP (1) JP4576052B2 (de)
AR (1) AR021534A1 (de)
AT (1) ATE249460T1 (de)
AU (1) AU1393000A (de)
DE (1) DE69911241T2 (de)
FR (1) FR2786770B1 (de)
WO (1) WO2000034279A1 (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804430B1 (fr) 2000-01-28 2002-03-22 Sanofi Synthelabo Derives de 4-heteroaryl-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
FR2809731B1 (fr) 2000-05-31 2002-07-19 Sanofi Synthelabo Derives de 1,4-diazabicyclo-[3.2.2] nonane-pheylisoxazole, leur preparation et leur application en therapeutique
FR2809732B1 (fr) * 2000-05-31 2002-07-19 Sanofi Synthelabo DERIVES DE 4(-2-PHENYLTHIAZOL-5-yl)-1,4-DIAZABICYCLO-[3.2.2] NONANE, LEUR PREPARATION ET LEUR APPLICATION ENTHERAPEUTIQUE
FR2809730B1 (fr) 2000-05-31 2002-07-19 Sanofi Synthelabo Derives de 1,4-diazabicyclo[3.2.2] nonanebenzoxazole, -benzothiazole et -benzimidazole, leur preparation et leur application therapeutique
US20020086871A1 (en) * 2000-12-29 2002-07-04 O'neill Brian Thomas Pharmaceutical composition for the treatment of CNS and other disorders
EP1231212B1 (de) * 2001-02-06 2006-12-20 Pfizer Products Inc. Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
FR2832712B1 (fr) * 2001-11-23 2004-02-13 Sanofi Synthelabo Derives de 4-(oxadiazol-3-yl)-1,4-diazabicyclo[3.2.2]nonane, leur preparation et leur application en therapeutique
FR2832713B1 (fr) * 2001-11-23 2004-02-13 Sanofi Synthelabo Derives de 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
FR2832714B1 (fr) * 2001-11-23 2004-07-16 Sanofi Synthelabo Derives de 4-(oxazolopyridin-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
FR2834511B1 (fr) * 2002-01-07 2004-02-13 Sanofi Synthelabo Derives de 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, leur preparation et leur application en therapeutique
CA2476896A1 (en) * 2002-02-26 2003-09-04 North Shore-Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
JP2006504690A (ja) * 2002-09-10 2006-02-09 ファイザー・プロダクツ・インク Ｃｎｓ及びその他の障害の治療に有用なジアザ二環式化合物
CN1326857C (zh) * 2002-09-30 2007-07-18 神经研究公司 新的1,4－二氮杂双环烷烃衍生物、其制备和应用
US7220741B2 (en) 2002-09-30 2007-05-22 Neurosearch A/S 1,4-diazabicycloalkane derivatives, their preparation and use
FR2845388B1 (fr) * 2002-10-08 2004-11-12 Sanofi Synthelabo Derives de 1,4-diazabicyclo[3.2.2]nonanecarboxamides, leur preparation et leur application en therapeutique
US7456171B2 (en) 2002-10-08 2008-11-25 Sanofi-Aventis 1,4-Diazabicyclo[3.2.2]nonanecarboxamide derivatives, preparation and therapeutic use thereof
US7223753B2 (en) 2002-11-11 2007-05-29 Neurosearch A/S Diazabicyclic biaryl derivatives
JP2006508109A (ja) * 2002-11-11 2006-03-09 ニューロサーチ、アクティーゼルスカブ １，４−ジアザビシクロ（３，２，２）ノナン誘導体、その製造方法及びその使用
EP1581223B2 (de) * 2002-12-06 2016-05-25 The Feinstein Institute for Medical Research Hemmung von entzündungen unter verwendungvon alpha-7-rezeptor verbindenden cholinergen agonisten
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
ES2285514T3 (es) * 2003-09-26 2007-11-16 Astrazeneca Ab Nonanos de amidicos.
KR20060125885A (ko) * 2004-02-04 2006-12-06 뉴로서치 에이/에스 콜린 수용체 조절제로서의 디아자바이사이클릭 아릴 유도체
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
WO2005092308A2 (en) 2004-03-25 2005-10-06 The Feinstein Institute For Medical Research Neural tourniquet
US7632831B2 (en) * 2004-05-07 2009-12-15 Memory Pharmaceuticals Corporation 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
EP1802258A4 (de) 2004-09-13 2015-09-23 Chrono Therapeutics Inc Biosynchrone transdermale arzneiabgabe
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
EP2298410B1 (de) 2004-12-27 2013-10-09 The Feinstein Institute for Medical Research Behandlung von entzündlichen Erkrankungen durch elektrische Stimulation des Vagusnervs
ATE495178T1 (de) 2005-02-16 2011-01-15 Neurosearch As Diazabicyclische arylderivate und ihre verwendung als chinolinergische liganden an nikotin- acetylcholin-rezeptoren
FR2889847B1 (fr) 2005-08-18 2007-10-05 Sanofi Aventis Sa Derives de 5-pyridazinyl-1-azabicyclo[3.2.1]octave, leur preparation en therapeutique.
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
NZ567048A (en) 2005-12-06 2010-12-24 Neurosearch As Novel diazabicyclic aryl derivatives and their medical use
WO2007090886A1 (en) 2006-02-10 2007-08-16 Neurosearch A/S 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
CA2641685A1 (en) 2006-02-10 2007-08-16 Neurosearch A/S 3-heteroaryl-3,9-diazabicyclo[3.3.1]nonane derivatives as nicotinic acetylcholine receptor agonists
AU2007213670A1 (en) 2006-02-10 2007-08-16 Neurosearch A/S 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP2049538A1 (de) 2006-05-30 2009-04-22 NeuroSearch A/S Neue 1,4-diazabicyclo[3.2.2]nonylpyrimidinylderivate und ihre medizinische verwendung
CN101772346B (zh) 2007-04-02 2014-05-07 帕金森氏病研究院 用于降低治疗副作用的方法和组合物
JP2010536726A (ja) * 2007-08-17 2010-12-02 ノイロサーチ アクティーゼルスカブ ニコチン性アセチルコリン受容体リガンドとして有用な新規１，４−ジアザ−ビシクロ〔３．２．２〕ノニルヘテロアリール誘導体
AU2008290647A1 (en) * 2007-08-17 2009-02-26 Neurosearch A/S 1,4-diaza-bicyclo(3.2.2)nonyl pyrimidinyl derivatives useful as nicotinic acetylcholine- receptor ligands
WO2009029614A1 (en) 2007-08-27 2009-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
DE102007053771A1 (de) * 2007-11-12 2009-05-14 Merck Patent Gmbh Organische Elektrolumineszenzvorrichtungen
EP2209781A1 (de) * 2007-11-14 2010-07-28 NeuroSearch AS Neue 1,4-diazabicyclo[3.2.2]nonylpyrimidinderivate und ihre medizinische verwendung
WO2009062988A1 (en) 2007-11-14 2009-05-22 Neurosearch A/S Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
WO2009146030A1 (en) 2008-03-31 2009-12-03 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of t-cell activity
EP2355893B1 (de) 2008-11-18 2013-12-25 Setpoint Medical Corporation Vorrichtungen zur optimierung der elektrodenplatzierung für antientzündungsstimulationen
WO2010084121A1 (en) * 2009-01-21 2010-07-29 Neurosearch A/S Novel diaza-bicyclononyl-pyrimidinyl derivatives and their medical use
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
EP2440284B1 (de) 2009-06-09 2018-09-12 Setpoint Medical Corporation Nervenmanschette mit tasche für einen bleifreien stimulator
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
WO2014169145A1 (en) 2013-04-10 2014-10-16 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
EP3636314B1 (de) 2009-12-23 2021-09-08 Setpoint Medical Corporation Nervenstimulatoren und systeme zur behandlung von chronischer entzündung
EP2707094B1 (de) 2011-05-09 2016-02-03 Setpoint Medical Corporation Einzelimpulsaktivierung des cholinergen entzündungshemmenden pfades zur behandlung chronischer entzündungen
TW201311698A (zh) * 2011-08-22 2013-03-16 Targacept Inc 作為神經元菸鹼乙醯膽鹼受體配位體之１，４－二氮雜雙環［３．２．２］壬烷
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 薬剤送達方法及びシステム
WO2016126807A1 (en) 2015-02-03 2016-08-11 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
EP3405255A4 (de) 2016-01-20 2019-10-16 Setpoint Medical Corporation Implantierbare mikrostimulatoren und induktive ladesysteme
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
US10695569B2 (en) 2016-01-20 2020-06-30 Setpoint Medical Corporation Control of vagal stimulation
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US11285306B2 (en) 2017-01-06 2022-03-29 Morningside Venture Investments Limited Transdermal drug delivery devices and methods
WO2019036470A1 (en) 2017-08-14 2019-02-21 Setpoint Medical Corporation TESTING TEST FOR STIMULATION OF NERVE WAVE
US11660443B2 (en) 2018-04-20 2023-05-30 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
EP3801732A4 (de) 2018-05-29 2022-04-27 Morningside Venture Investments Limited Verfahren und systeme zur wirkstofffreisetzung
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
KR20230012585A (ko) 2020-05-21 2023-01-26 더 파인스타인 인스티튜츠 포 메디칼 리서치 미주 신경 자극을 위한 시스템들 및 방법들

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994460A (en) * 1989-06-01 1991-02-19 Bristol-Myers Squibb Co. Agents for treatment of brain ischemia
DE69416869T2 (de) * 1993-12-29 1999-07-01 Pfizer Diazabicyclische neurokinin antagonisten
US5478939A (en) * 1994-07-20 1995-12-26 American Cyanamid Company (R,R) and (S,S) 2,5-diazabicyclo [2,2,1]heptane derivatives
JP2668670B2 (ja) * 1995-03-24 1997-10-27 日本たばこ産業株式会社 ジアザビシクロ［３．３．１］ノナン誘導体、その中間体及びその医薬用途
WO1996030372A1 (fr) * 1995-03-24 1996-10-03 Japan Tobacco Inc. Derives diazabicyclo[3.3.1]nonane et leurs intermediaires, leur application therapeutique et procedes de production

Also Published As

Publication number Publication date
DE69911241T2 (de) 2004-07-01
US6407095B1 (en) 2002-06-18
AR021534A1 (es) 2002-07-24
EP1135389B1 (de) 2003-09-10
WO2000034279A1 (fr) 2000-06-15
FR2786770A1 (fr) 2000-06-09
JP2002531565A (ja) 2002-09-24
EP1135389A1 (de) 2001-09-26
JP4576052B2 (ja) 2010-11-04
ATE249460T1 (de) 2003-09-15
AU1393000A (en) 2000-06-26
FR2786770B1 (fr) 2001-01-19

Similar Documents

Publication Publication Date Title
DE69911241D1 (de) 1,4-diazabicyclo(3.2.2)nonanderivate, deren herstellung und deren verwendung in heilkunde
DE69915693D1 (de) 2,5-diazabicyclo(2.2.1)heptanderivate, deren herstellung und deren verwendung in heilkunde
DE69806880D1 (de) Resistzusammensetzungen, ihre Herstellung und ihre Verwendung für Bildaufzeichnungsverfahren
DE60034683D1 (de) 3(5)-ureido-pyrazolderivate, deren herstellungsverfahren und verwendung als krebshemmende mittel
DE60023012D1 (de) 3(5)-amino-pyrazolderivate, deren herstellungsverfahren und verwendung als krebshemmende mittel
DE69427117D1 (de) Organometall-Fluorenylverbindungen deren Herstellung und deren Verwendung
DE69527451T2 (de) Organometall-Fluorenylverbindungen, deren Herstellung und deren Verwendung
DE59911249D1 (de) Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung
DE69928140D1 (de) Antipicornavirale Verbindungen, deren Herstellung und Verwendung
ATE302604T1 (de) Thienylazolylalkoxyethanamine, deren herstellung und deren verwendung als medikamente
ATE380793T1 (de) N-phenyl-alkylsulfonamid-derivate, deren herstellung und deren verwendung als alpha1a/1l- adrenoceptor agonisten
ATE258549T1 (de) Oxazolidindion-derivate, ihre herstellung und verwendung
ATE239693T1 (de) 3,3-diarylpropylamine , ihre verwendung und herstellung
DE59905572D1 (de) Substituierte 4-amino-2-aryl-pyrimidine, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate
DE60235547D1 (de) En daraus, deren herstellung und verwendung
DE69835433D1 (de) Disulfid-vernetzte glycoprotein-hormone, ihre herstellung und verwendung
DE60008419D1 (de) Farbstoffpräparate, deren herstellung und deren verwendung
ATE242197T1 (de) 3-amino-3-arylpropan-1-ol-derivate, deren herstellung und verwendung
DE60005690D1 (de) Titanverbindungen, deren herstellung und verwendung
DE69204909T2 (de) Amino-Urazilderivate, deren Herstellung und Verwendung.
ATE212346T1 (de) 3-substituierte tetrahydropyridopyrimidinon- derivate, ihre herstellung und verwendung
DE69735123D1 (de) Trehalose phosphorylase, deren Herstellung und Verwendung
DE59501950D1 (de) Isolongifolanol-Derivate, ihre Herstellung und ihre Verwendung
DE69811651T2 (de) Enthaarungszusammensetzungen, die bereitung und die verwendung derselben
ATE263138T1 (de) 3-amino-3-arylpropan-1-ol-derivate, deren herstellung und verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-AVENTIS, PARIS, FR

R082 Change of representative

Ref document number: 1135389

Country of ref document: EP

Representative=s name: TER MEER STEINMEISTER & PARTNER GBR PATENTANWA, DE